Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493818 · ClinicalTrials.gov registry record · Phase 1
Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00493818 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 70 participants.
The verdict
NCT00493818, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study is a first time in human, Phase I, open-label study to determine recommended doses and schedules, based on maximum tolerated doses and biologically active doses, for the AKT inhibitor GSK690693.
Interventions
- DRUG GSK690693
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493818
The ClinicalTrials.gov registry entry for NCT00493818 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK690693 is the first listed.
NCT00493818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493818 about?
NCT00493818 is a clinical study titled "Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693". This study is a first time in human, Phase I, open-label study to determine recommended doses and schedules, based on maximum tolerated doses and biologically active doses, for the AKT inhibitor GSK690693.
What is the current status of trial NCT00493818?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2007-04. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00493818?
The interventions under investigation include: GSK690693 (DRUG).
Who is sponsoring clinical trial NCT00493818?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.